Aspirin to target arterial events in chronic kidney disease (attack): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

HIGHLIGHTS

• who: Hugh Gallagher from the SW Thames Renal Unit, Epsom and St Helier University Hospitals NHS Trust, Epsom, UK have published the research: Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease, in the Journal: (JOURNAL)
• what: The aim of the ATTACK study is to test the hypothesis that low-dose (75 mg non-enteric coated) aspirin reduces the risk . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.